Amgen Narrows 340B Purchasing For Neulasta To Enhance Transparency, Firm Says
This article was originally published in The Pink Sheet Daily
Executive Summary
An advocacy group representing safety net hospitals has written to Amgen urging the company to withdraw the plan for changing distribution of Neulasta, maintaining it will increase costs and add administrative hurdles.